We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV
Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group.
BACKGROUND Vinorelbine , a semisynthetic vinca alkaloid , represents a well-tolerated treatment for elderly patients with advanced non-small-cell lung cancer ( NSCLC ) . We explored the quality of life ( QoL ) of such patients in a multicenter r and omized trial that compared vinorelbine treatment with supportive care alone . METHODS Eligible patients were 70 years of age or older , had stage IV or IIIB NSCLC that was ineligible for radiotherapy , and had a performance status of 0 - 2 ( a status of fully active to a status of capable of all self-care but unable to work ) .  Vinorelbine was given intravenously on days 1 and 8 of a 21-day treatment cycle , for a total of six cycles . QoL was evaluated with European Organization for Research and Treatment of Cancer question naires QLQ-C30 and QLQ-LC13 , and the QoL data were analyzed by fitting a linear mixed model for each QoL scale . Survival curves were plotted and were compared with the Mantel-Haenszel test . Relative hazards of death and 95 % confidence intervals ( CIs ) were estimated by the Cox model . RESULTS Investigators , blinded to the results , stopped the trial early because of a low enrollment rate . ( From April 1996 to November 1997 , 191 of the 350 targeted patients were r and omly assigned . ) Data from 161 patients have been analyzed . Vinorelbine-treated patients scored better than control patients on QoL functioning scales , and they reported fewer lung cancer-related symptoms but reported worse toxicity-related symptoms . There was a statistically significant ( two-sided P = .03 ) survival advantage for patients receiving vinorelbine ; median survival increased from 21 to 28 weeks in the vinorelbine-treated group . The relative hazard of death for vinorelbine-treated patients was 0.65 ( 95 % CI = 0.45 - 0.93 ) . CONCLUSION Vinorelbine improves survival of elderly patients with advanced NSCLC and possibly improves overall
We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV